Results 131 to 140 of about 344,829 (184)

Clinical and economic benefits of bivalent respiratory syncytial virus prefusion F (RSVpreF) maternal vaccine for prevention of RSV illness in infants: A cost-effectiveness analysis for Singapore

Background: Respiratory syncytial virus (RSV) is a leading cause of respiratory tract infections in children. A novel bivalent RSV prefusion F protein subunit (RSVpreF) vaccine has recently been approved by the Health Sciences Authority (HSA) in ...
Dashraath, Pradip, Kefalogianni, Rengina, Zhang, Jessie, Law, Amy W., Mendes, Diana, Thakkar, Karan, Yung, Chee Fu, Tagore, Shephali   +7 more
core   +1 more source

Immune responses after two inactivated COVID-19 vaccine doses, a heterologous third dose and subsequent boosting with bivalent mRNA in adults

Scientific Reports
To evaluate immune response and safety of a bivalent mRNA booster (ancestral/BA.4/5) vaccine in individuals who had received inactivated COVID-19 vaccine with different heterologous boost regimens.
Sant Muangnoicharoen, Saranath Lawpoolsri, Juthaporn Cowan, Viravarn Luvira, Anan Jongkaewwattana, Sira Nanthapisal, Weerapong Phumratanaprapin, Supitcha Kamolratanakul, Narumon Thanthamnu, Chatnapa Duangdee, Punnee Pitisuttithum   +10 more
doaj   +1 more source

Effectiveness of BNT162b2 BA.4/5 Bivalent COVID-19 Vaccine against Long COVID Symptoms: A US Nationwide Study

Background: Long COVID has become a central public health concern. This study characterized the effectiveness of BNT162b2 BA.4/5 bivalent COVID-19 vaccine (bivalent) against long COVID symptoms.
Alexandra Berk, Thomas M. Porter, Joseph C. Cappelleri, Manuela Di Fusco, Jinma Ren, Kristen E. Allen, Santiago M. C. Lopez, Xiaowu Sun, Alon Yehoshua, Mary B. Alvarez, Laura Puzniak   +10 more
core   +1 more source

The development of DNA vaccine and adjuvant against Actinobacillus pleuropneumoniae

, 2012
[[abstract]]Actinobacillus pleuropneumoniae (APP) is the etiological agent of swine pleuropneumonia that causes critical economic losses in swine industry.
Yang, Wen-Jen; Lu, Yu-Chun; Chiang, Chung-Hao; Yeh, Chien-Ju; Huang, Li-Pu
core  

Recombinant Human Papillomavirus Bivalent Vaccine [PDF]

, 2020
openaire   +1 more source

Investigation on the Efficacy of Salmonella Bivalent Vaccine

IOSR Journal of Agriculture and Veterinary Science, 2013
openaire   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Bivalent Cholera and Typhoid Vaccine

Drugs, 1999
The live attenuated vaccine strains Vibrio cholerae CVD 103-HgR and Salmonella typhi Ty21a can be combined into an oral bivalent vaccine without compromising the immunogenicity of the individual vaccine strains. Seroconversion rates of 87 to 94% for Inaba vibriocidal antibodies and 72 to 91% for anti-S.
R H, Foster, S, Noble
  +5 more sources

Comparison of Bivalent and Monovalent mRNA Vaccine Boosters

Clinical Infectious Diseases, 2023
Abstract In this cohort study conducted in Hong Kong where both bivalent and monovalent formulations of BNT162b2 were available, there were no significant differences in the mortality or hospitalization between those who received bivalent and monovalent mRNA as second boosters.
Carlos K H Wong, Kristy T K Lau, Ivan C H Au, Eric H Y Lau, Benjamin J Cowling   +4 more
openaire   +2 more sources

Vaccination Recommendations for Bivalent mRNA COVID-19 Vaccines

The Medical Letter on Drugs and Therapeutics, 2023
Vaccination Recommendations for Bivalent mRNA COVID-19 ...
openaire   +2 more sources

Efficacy of a trivalent Haemophilus paragallinarum vaccine compared to bivalent vaccines

Veterinary Microbiology, 1992
The efficacy of a trivalent oil-adjuvant Coryza vaccine containing serotypes A, B and C of Haemophilus paragallinarum has been compared with that of a bivalent oil-adjuvant Coryza vaccine containing serotypes A and C and that of a commercially available, bivalent A1(OH)3-potentiated vaccine, containing types A and C.
A A, Jacobs, W, Cuenen, P K, Storm
openaire   +2 more sources